|
US 11,806,366 B2 |
|
| Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| Heiko Schuster, Tuebingen (DE); Janet Peper, Tuebingen (DE); Philipp Wagner, Stuttgart (DE); and Hans-Georg Rammensee, Tuebingen (DE) |
| Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on Apr. 30, 2021, as Appl. No. 17/245,031. |
| Application 17/245,031 is a continuation of application No. 17/123,585, filed on Dec. 16, 2020. |
| Application 17/123,585 is a continuation of application No. 16/905,550, filed on Jun. 18, 2020, granted, now 10,888,587, issued on Jan. 12, 2021. |
| Application 16/905,550 is a continuation of application No. 16/777,919, filed on Jan. 31, 2020, granted, now 10,722,538, issued on Jul. 28, 2020. |
| Application 16/777,919 is a continuation of application No. 16/556,549, filed on Aug. 30, 2019, granted, now 10,639,331, issued on May 5, 2020. |
| Application 16/556,549 is a continuation of application No. 15/813,610, filed on Nov. 15, 2017, granted, now 10,463,696, issued on Nov. 5, 2019. |
| Application 15/813,610 is a continuation of application No. 15/209,845, filed on Jul. 14, 2016, granted, now 9,889,159, issued on Feb. 13, 2018. |
| Claims priority of provisional application 62/192,670, filed on Jul. 15, 2015. |
| Claims priority of application No. 1512369 (GB), filed on Jul. 15, 2015. |
| Prior Publication US 2021/0260122 A1, Aug. 26, 2021 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 39/00 (2006.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 15/115 (2010.01); C12P 21/02 (2006.01); C12Q 1/6881 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01) |